Daiichi Sankyo
California Life Sciences is excited to announce the upcoming Daiichi Sankyo Partnering Day. To explore potential collaboration opportunities through 1:1 meetings with Daiichi Sankyo leadership, complete the application by the deadline below. Selected companies will be notified directly.
About This Event
Representatives from Daiichi Sankyo will be in attendance and are seeking 1:1 meetings with early-stage and clinical-stage life sciences companies. Daiichi Sankyo welcomes opportunities that enhance or support their pipeline of medicines to address unmet medical needs in life-threatening and debilitating disease areas.
Objectives include asset licensing, external research agreements, and regionally focused collaborations.
Applying does not guarantee a meeting; selected companies will be contacted directly.
01
submit your application
Complete the application form with accurate, specific details about your company and technology to ensure the best fit.
02
selection & notification
Daiichi Sankyo reviews all applications and selects participating companies. Selected applicants will be notified directly prior to the event.
03
attend in person
Selected companies must be available to attend in person. The day includes 1:1 meetings, information sessions, and a networking reception.
About Daiichi Sankyo
Daiichi Sankyo is a global healthcare company headquartered in Japan, committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world.
With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society.
The Daiichi Sankyo Research Institute San Diego serves as a key hub for external innovation and partnership across the West Coast region.
global headquarters
Tokyo, Japan — with an expanding research presence in San Diego, CA
scientific heritage
125+ years of drug discovery and development
partnership goals
Asset licensing, external research agreements, and regionally focused collaborations
Areas of Interest
Daiichi Sankyo is seeking collaborators with complementary expertise across three focus areas. Please ensure your application clearly reflects alignment with one or more of the criteria below.
01
oncology
Preference for assets with early safety and efficacy data. Major indications with emphasis on breast, lung, colorectal and pancreatic cancers.
- Clinical programs with stand-alone potential
- Targets/MOAs combinable with Daiichi Sankyo ADCs
- Must be willing to engage in global licensing
02
non-oncology / specialty medicine
Late-stage assets seeking regional partnerships (Phase 2 ongoing or later). Clinical-stage products with potential to launch by 2030.
- Europe & Japan: Cardiovascular and metabolic diseases
- Japan only: CVM, CNS, Immunology (excl. ophthalmology & rare diseases)
03
enabling research & technologies
Innovative platforms and technologies across therapeutic and modality-based focus areas.
- Novel tumor-specific binders, TME-responsive biologics
- Enhancing technologies of TCE functionality, tumor selectivity of cytokines
- Heterobifunctional protein degraders (TPDs), multi-specific antibodies
- Disease-relevant target ID: cardiovascular and CNS disorders
Ready to apply?
Please provide accurate and specific responses to ensure the best fit with the appropriate Daiichi Sankyo team. Only completed applications will be accepted.
Key Dates for Daiichi Sankyo Partnering Day
June 22, 2026
Applications open
August 8, 2026
Applications close
October 21, 2026
Pharma partnering day
Recent Daiichi Sankyo Research Institute San Diego Collaborations
Daiichi Sankyo has entered into a research collaboration with SylamoreBio that focuses on central nervous system applications, utilizing the SyLEC module—a specialized delivery platform engineered to transport therapeutic cargo across complex biological barriers to achieve high-efficiency cellular uptake and broad tissue penetration..
Daiichi Sankyo has entered into a research collaboration with Qymune on a multi-phase to evaluate its next-generation T-cell engager platform for a novel oncology program to advance new approaches to targeted cancer therapies.
Daiichi Sankyo has entered into a research collaboration with Voro Therapeutics to evaluate its PrimeBody platform for tumor-activated antibody drug conjugates to advance more precise and targeted approaches to cancer treatment.
Regional Partners
CLS is partnering with Oregon Life Sciences and UtahBio to connect their member companies with Daiichi Sankyo, expanding access to partnering opportunities across the broader regional ecosystem.
